Explore the impact of AI and LLMs on scientific workflows and the challenges of their adoption in the life sciences field.

Chief Scientific Officer at Solvias reveals how CROs are overcoming manufacturing challenges and harnessing AI to fast-track the development of groundbreaking cell and gene therapies. Daniel Galbraith ...

Tyra Biosciences has announced new data showing that its investigational therapy, TYRA-300, improves bone growth and corrects skeletal abnormalities in preclinical models of achondroplasia and ...

The partnership allows for the further development of AI-designed RNA-targeted therapies for a range of diseases. Creyon Bio, Inc. (Creyon) has announced a landmark global licensing and multi-target ...

A new study reveals how tumours hijack fat metabolism to suppress immune responses – and how a novel antibody, PLT012, may reverse this effect, offering new hope for treating immunotherapy-resistant ...

Huntington’s disease remains a major challenge, but allele-selective gene editing offers new hope. By targeting only the mutant gene, this approach could provide a one-time, durable treatment. Life ...

Cell and gene therapy is rapidly transforming the treatment of complex diseases, yet scaling production efficiently remains a challenge. Dr Tia Harmon from PHC Corporation of North America explores ...

Enedra Therapeutics has secured new funding to advance its AI-driven CASPAROV platform, aimed at developing therapies for difficult-to-treat cancers The London based drug discovery company, Enedra ...

CatalYm announces new preclinical data showing that its clinical-stage antibody, visugromab, can overcome resistance to antibody-drug conjugates (ADCs), showing potential to restore anti-tumour immune ...

Researchers at the University of Michigan have discovered a powerful combination therapy that eradicates pancreatic tumours in preclinical models, offering hope for new treatments against one of the ...

Outdated clinical development systems are slowing breakthroughs like gene therapies and precision medicine. This article explores how a flexible, on-demand approach can accelerate drug development and ...

Researchers at Moffitt Cancer Center have discovered that blocking a chemical process called nitrosylation can make aggressive NRAS-mutant melanoma more responsive to treatment. This form of skin ...